What are the practical steps in choosing, initiating, and monitoring steroid-sparing agents (SSA) in the management of steroid-dependent or frequently relapsing nephrotic syndrome (NS) in children?

Practical Steps in Steroid-Sparing Agent Management for Steroid-Dependent/Frequently Relapsing Nephrotic Syndrome in Children

When to Initiate Steroid-Sparing Agents

Steroid-sparing agents should be prescribed for all children with steroid-dependent nephrotic syndrome and for those with frequently relapsing nephrotic syndrome who develop serious glucocorticoid-related adverse effects. 1

Clear Indications:

• Steroid-dependent NS: All cases require steroid-sparing therapy 1
• Frequently relapsing NS with steroid toxicity: Growth failure, obesity, hypertension, diabetes, osteoporosis, behavioral concerns, or cataracts 1
• Frequently relapsing NS without toxicity: Consider low-dose alternate-day prednisone first before introducing steroid-sparing agents 1

Choice of Steroid-Sparing Agent

The 2025 KDIGO guidelines list steroid-sparing options in an unbiased order: calcineurin inhibitors, cyclophosphamide, levamisole, mycophenolate mofetil, and rituximab—with no clear therapeutic superiority of any agent over others. 1

Decision Framework Based on Clinical Context:

First-Line Options by Setting:

Resource-limited settings: Levamisole as first-line, then cyclophosphamide 1

Resource-adequate settings: Choose based on these factors 1:

• Route preference: Oral agents (levamisole, cyclophosphamide, calcineurin inhibitors, mycophenolate) vs. intravenous (rituximab)
• Monitoring capability: Calcineurin inhibitors require drug level monitoring; cyclophosphamide requires blood count monitoring
• Side effect tolerance: See monitoring section below
• Disease pattern: Cyclophosphamide and levamisole may be more indicated for frequently relapsing (vs. steroid-dependent) disease 1

Specific Agent Selection:

Levamisole 1, 2:

• Dose: 2.5 mg/kg on alternate days
• Duration: At least 12 months
• Best for: First-line in resource-limited settings; frequently relapsing pattern
• Advantages: Well-tolerated, oral, inexpensive
• Key side effects: Cytopenia, elevated liver enzymes 3

Cyclophosphamide 1, 2:

• Dose: 2 mg/kg/day (maximum 3 mg/kg/day)
• Duration: 8-12 weeks
• Maximum cumulative dose: 168 mg/kg
• Best for: Frequently relapsing pattern; definitive course desired
• Critical caveat: Start only after achieving remission with corticosteroids 2
• Major pitfall: Avoid second courses due to cumulative gonadal toxicity 2, 3
• Side effects: Transient leukopenia (18.5%), gonadal toxicity 4, 3

Calcineurin Inhibitors (Cyclosporine or Tacrolimus) 1, 2:

• Cyclosporine: 3-5 mg/kg/day in divided doses (target trough: 100-175 ng/mL) 5
• Tacrolimus: 0.05-0.15 mg/kg/day in divided doses (target trough: 5-10 ng/mL) 5, 6
• Duration: At least 12 months 2
• Best for: Steroid-dependent pattern; when sustained therapy needed
• Advantages: Effective maintenance therapy
• Side effects: Cyclosporine—gingival hypertrophy, hirsutism; Tacrolimus—diabetes risk; Both—nephrotoxicity with chronic use 1, 3

Mycophenolate Mofetil 2, 6:

• Dose: 1200 mg/m²/day (or 20-30 mg/kg/day) in two divided doses
• Duration: At least 12 months
• Best for: Alternative when calcineurin inhibitors contraindicated
• Side effects: Cytopenia, diarrhea 3, 6

Rituximab 7, 2, 4:

• Dose: 375 mg/m² as single intravenous infusion
• Premedication: Acetaminophen and antihistamine
• Best for: Steroid-dependent NS with continuing relapses despite other agents; serious adverse effects from other therapies
• Advantages: 84.2% one-year relapse-free survival vs. 58.6% with cyclophosphamide; 73.7% achieved complete steroid withdrawal within 3 months vs. 29.6% with cyclophosphamide 4
• Consider second dose: After 1-3 months if B-cell recovery occurs with early relapse signs 7
• Side effects: Infusion reactions (5%), increased infection risk, prolonged neutropenia 4, 3

Initiation Protocol

Pre-Treatment Requirements:

Before starting any steroid-sparing agent 1, 2:

• Ensure child is in remission (for cyclophosphamide specifically)
• Baseline kidney function assessment (GFR or eGFR)
• Baseline complete blood count
• For calcineurin inhibitors: Baseline blood pressure, glucose
• For rituximab: Screen for active infections

Concurrent Steroid Management:

During steroid-sparing agent initiation 2:

• Continue alternate-day prednisone initially
• Taper prednisone gradually as steroid-sparing agent takes effect
• Goal: Minimize or eliminate steroid exposure while maintaining remission

Monitoring Protocol

Agent-Specific Monitoring:

Levamisole 2, 3:

• Complete blood count every 2-4 weeks initially, then monthly
• Liver function tests monthly
• Watch for: Neutropenia, elevated transaminases

Cyclophosphamide 2, 4:

• Complete blood count weekly during treatment
• Stop immediately if: Severe leukopenia (WBC <3000/μL) or neutropenia
• Monitor for: Hemorrhagic cystitis symptoms
• Ensure adequate hydration during treatment

Calcineurin Inhibitors 1, 2:

• Drug trough levels every 2 weeks until stable, then monthly
• Serum creatinine every 2-4 weeks
• Blood pressure at each visit
• Critical monitoring: Assess for nephrotoxicity—any decreasing kidney function warrants dose adjustment or discontinuation 1, 2
• For tacrolimus: Monitor glucose periodically

Mycophenolate Mofetil 2, 6:

• Complete blood count monthly
• Monitor for gastrointestinal symptoms
• Watch for: Cytopenia, diarrhea

Rituximab 7, 4:

• Monitor during infusion for reactions (generalized rash, anaphylaxis)
• CD19/CD20 B-cell counts every 1-3 months post-infusion
• Key decision point: B-cell recovery with early relapse signs indicates need for second dose 7
• Monitor for opportunistic infections

Universal Monitoring for All Agents:

Ongoing assessment 2:

• Urine protein (dipstick) at home monitoring for relapse detection
• Quantification of proteinuria (urine protein/creatinine ratio) to assess treatment response
• Growth parameters (height, weight) at each visit
• Blood pressure at each visit
• Assessment for steroid-related complications

Common Pitfalls and How to Avoid Them

Pitfall 1: Starting cyclophosphamide during active relapse 2

• Solution: Always achieve remission with steroids first before initiating cyclophosphamide

Pitfall 2: Giving second course of alkylating agents 2

• Solution: Use alternative steroid-sparing agents for subsequent treatment needs due to cumulative gonadal toxicity

Pitfall 3: Inadequate treatment duration 2

• Solution: Continue most steroid-sparing agents (except cyclophosphamide) for minimum 12 months

Pitfall 4: Missing calcineurin inhibitor nephrotoxicity 1, 2

• Solution: Regular creatinine monitoring; consider kidney biopsy if decreasing function to assess for CNI nephrotoxicity

Pitfall 5: Premature steroid withdrawal 2

• Solution: Taper steroids gradually only after steroid-sparing agent demonstrates efficacy

Pitfall 6: Inadequate parent education 1

• Solution: Teach parents home urine dipstick monitoring and early relapse recognition

When to Consider Kidney Biopsy

Biopsy indications during steroid-sparing therapy 1, 2:

• Late failure to respond following initial steroid response
• High suspicion for different underlying pathology
• Decreasing kidney function in children receiving calcineurin inhibitors (to assess CNI nephrotoxicity)
• Multiple relapses without previous histological confirmation